

PRESS CLIPPING SHEET

PUBLICATION:	Daily News
DATE:	11-June-2017
COUNTRY:	Egypt
CIRCULATION:	80,000
TITLE :	Sandoz Egypt launches its first recombinant human growth hormone deficiency patients
PAGE:	Back Page
ARTICLE TYPE:	Agency-Generated News
REPORTER:	Staff Report
AVE:	5,600

PRESS CLIPPING SHEET

Sandoz Egypt launches
its first recombinant
human growth hormone
to treat growth hormone
deficiency patients

Sandoz, a Novartis Division, announced today a breakthrough for Growth Hormone Deficiency (GHD) patients in Egypt by launching the first follow-on version of a biopharmaceutical medicine approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Sandoz, the global leader in biosimilars, "has seven decades of experience in biotechnologies using state-of-the-art technologies and facilities," said Thodoris Dimopoulos, Sandoz country head, Egypt and Libya. "The launch of our first Sandoz biologic medicine in Egypt, is not only a milestone for the company, but more importantly it paves the way for redefining patients' access to treatment by offering a high-quality, more affordable version of this important medicine."

"Sandoz maintains its commitment to bringing high-quality biologic medicines to patients and healthcare professionals around the world. Sandoz' purpose is to discover new ways to improve people's lives, by pioneering novel approaches to help people around the world access high-quality medicine and contributing to improving society's ability to support growing healthcare needs," said Dimopoulos.